Loading, please wait...
Join Dr. Nicole Short for this 45-minute presentation where she discusses the characteristics of episodic migraine followed by an explanation of the mechanism of calcitonin gene-related peptide (CGRP) antagonists. An overview of current American Academy of Neurology recommendations and the European Headache Federation guidance on CGRP antagonists for episodic migraine prevention will be discussed. A literature review over the critical trials of injectable CGRP antagonists along with a trial of the first-line agent, topiramate will be presented. The findings of these trials will be compared and contrasted in order to help define the role and place in therapy for CGRP antagonists.
To learn more about this activity, including speaker information and learning objectives, expand the module below (click the +). Pharmacists can earn 0.75 contact hour of knowledge-based CE credit at the completion of this activity.
Fee
$8.00
CE Hours
0.75
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
|
St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To learn more about the specific program information, including universal activity numbers (UAN's) and learning objectives, please expand the modules below. Following successful completion of an evaluation, CE credit will be automatically reported to NABP through the CPE Monitor system, using the NABP ePID numbers and date of birth (MMDD) stored in participants' user profiles. Follow this link to learn more about CPE Monitor and the credit reporting process » Participants are responsible for ensuring receipt of credit; no credit can be corrected or awarded if more than 60 days have passed from the date of the event or if the home study is expired.
It is the policy of St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in this program are expected to disclose to the program audience any real or apparent conflicts of interest related to the content of the presentation.
|
Requirements for CE Credit
To claim credit for this session, participants must complete the following steps:
- Visit this site. Make sure you are logged in and registered before proceeding.
- Complete an evaluation by clicking the green evaluation button
- Enter the evaluation code that was given to you at the end of the session you attended.
- Answer all questions honestly - we appreciate your feedback! All responses are stored anonymously.
- Click submit. As soon as you submit, a report containing the NABP ePID and DOB stored in your profile will be automatically sent to CPE Monitor.
- Please allow up to 48 hours for processing. Your credit should appear in your NABP profile online.
If you experience difficulty, please contact our office so that we may assist you. We are happy to help!
Participants are responsible for ensuring accuracy of credit reporting and receipt of credit. It is recommended that participants log on and review the information under "my account" prior to submitting the evaluation. NABP ePID and date of birth must be accurate for credit reporting to occur. Evaluations cannot be reopened after 14 days.
Participants are encouraged to check their NABP e-profiles for receipt of credit within one week of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact our office as soon as possible. To best comply with ACPE's CE credit reporting policy, the University of health Sciences and Pharmacy in St. Louis is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
Learn more! Click the + symbol to expand.
This presentation will begin with an introduction to the characteristics of episodic migraine followed by an explanation of the mechanism of calcitonin gene-related peptide (CGRP) antagonists. An overview of current American Academy of Neurology recommendations and the European Headache Federation guidance on CGRP antagonists for episodic migraine prevention will be discussed. A literature review over the critical trials of injectable CGRP antagonists along with a trial of the first-line agent, topiramate will be presented. The findings of these trials will be compared and contrasted in order to help define the role and place in therapy for CGRP antagonists.
Objectives
- Differentiate episodic migraine from other types of migraine conditions
- Describe the mechanism of calcitonin gene-related peptide (CGRP) antagonists in the prevention of migraine
- Summarize the role of injectable GCRP antagonists in the prevention of episodic migraine
- Identify a patient who could benefit from CGRP antagonist therapy for prevention of episodic migraine
Speaker(s)/Author(s)
|
Nicole Short, Pharm.D. |
Activity Number
0033-0000-22-005-H01-P
Release Date:
Jan 24, 2022
Credit Expiration Date:
Jan 24, 2025
CE Hours
0.75
Fee
$8.00
